Humana (NYSE:HUM) Price Target Increased to $322.00 by Analysts at JPMorgan Chase & Co.

Humana (NYSE:HUM) had its price objective hoisted by JPMorgan Chase & Co. from $288.00 to $322.00 in a report released on Thursday, BenzingaRatingsTable reports. The firm currently has an overweight rating on the insurance provider’s stock.

A number of other analysts also recently weighed in on HUM. Piper Jaffray Companies increased their price target on Humana from $315.00 to $341.00 and gave the stock an overweight rating in a report on Thursday. SunTrust Banks increased their price target on Humana to $340.00 and gave the stock a hold rating in a report on Thursday. Oppenheimer decreased their price target on Humana from $373.00 to $350.00 and set an outperform rating for the company in a report on Thursday, May 2nd. Citigroup decreased their price target on Humana from $362.00 to $302.00 and set a buy rating for the company in a report on Thursday, May 2nd. Finally, Morgan Stanley decreased their price target on Humana from $331.00 to $315.00 and set an overweight rating for the company in a report on Friday, July 12th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the stock. Humana has an average rating of Buy and an average target price of $341.21.

Humana stock traded down $4.26 during trading hours on Thursday, reaching $293.93. 1,693,224 shares of the company’s stock were exchanged, compared to its average volume of 1,143,401. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.65. The stock’s 50 day moving average price is $272.19. Humana has a twelve month low of $225.65 and a twelve month high of $355.88. The firm has a market cap of $40.28 billion, a price-to-earnings ratio of 20.20, a PEG ratio of 1.29 and a beta of 0.85.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $5.24 by $0.81. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm had revenue of $16.25 billion during the quarter, compared to the consensus estimate of $15.88 billion. During the same period last year, the business posted $3.96 EPS. The business’s revenue was up 13.9% compared to the same quarter last year. On average, research analysts expect that Humana will post 17.65 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. 1ST Source Bank boosted its position in shares of Humana by 2.8% during the 1st quarter. 1ST Source Bank now owns 1,414 shares of the insurance provider’s stock worth $376,000 after purchasing an additional 39 shares in the last quarter. Cornerstone Advisors Inc. boosted its position in shares of Humana by 13.5% during the 2nd quarter. Cornerstone Advisors Inc. now owns 353 shares of the insurance provider’s stock worth $94,000 after purchasing an additional 42 shares in the last quarter. Regentatlantic Capital LLC boosted its position in shares of Humana by 0.4% during the 2nd quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock worth $2,551,000 after purchasing an additional 42 shares in the last quarter. Nachman Norwood & Parrott Inc boosted its position in shares of Humana by 5.0% during the 1st quarter. Nachman Norwood & Parrott Inc now owns 1,058 shares of the insurance provider’s stock worth $281,000 after purchasing an additional 50 shares in the last quarter. Finally, Kovack Advisors Inc. boosted its position in shares of Humana by 2.6% during the 1st quarter. Kovack Advisors Inc. now owns 2,009 shares of the insurance provider’s stock worth $534,000 after purchasing an additional 51 shares in the last quarter. 92.49% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: Rule of 72

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.